Guizhounli Pharmaceutical Co (SHSE:603439) Total Equity: ¥1,561 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603439 Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
86 GF Score
Price ¥9.83
GF Value ¥14.93
Valuation Significantly Undervalued
! 10 Warning Signs
View Full Analysis

What is Guizhounli Pharmaceutical Co Total Equity?

Guizhounli Pharmaceutical Co SHSE:603439 -2.58% 86 Total Equity is ¥1,561 Mil as of Mar. 2026. GuruFocus rates SHSE:603439 with a GF Score™ of 86/100 and a GF Value™ of ¥14.93 (Significantly Undervalued). The stock has 10 warning signs investors should review.

Guizhounli Pharmaceutical Co's total equity for the quarter that ended in Mar. 2026 was ¥1,561 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Guizhounli Pharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Guizhounli Pharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co Total Equity Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,032.07 1,238.22 1,709.35 1,594.63 1,512.23

Guizhounli Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,640.87 1,549.03 1,548.15 1,512.23 1,560.68
SHSE:603439
86GF Score
Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guizhounli Pharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Guizhounli Pharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2847.923-1335.692
=1,512

Guizhounli Pharmaceutical Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2810.723-1250.049
=1,561

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥1,561 Mil mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a Total Equity of ¥1,561 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Guizhounli Pharmaceutical Co and its competitors.
Is Guizhounli Pharmaceutical Co's Total Equity too high?
Guizhounli Pharmaceutical Co's current Total Equity is ¥1,561 Mil. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Total Equity compare to ZTS and UTHR?
Guizhounli Pharmaceutical Co's Total Equity of ¥1,561 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Guizhounli Pharmaceutical Co and its competitors. Guizhounli Pharmaceutical Co's current Total Equity is ¥1,561 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.93, compared to a current price of ¥9.83 — trading 34.2% below its estimated fair value. The current Total Equity is ¥1,561 Mil. Guizhounli Pharmaceutical Co's overall GF Score™ is 86/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Total Equity is ¥1,561 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥9.83 is trading 34.2% below its estimated GF Value™ of ¥14.93. GuruFocus considers Guizhounli Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:603439:

  • Total Equity: ¥1,561 Mil
  • GF Value™: ¥14.93 vs. price of ¥9.83 (34.2% below fair value)
  • GF Score™: 86/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guizhounli Pharmaceutical Co Business Description

Address Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
86GF Score

Get the complete analysis for SHSE:603439

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.83
Price
¥14.93
GF Value